2019考研英語閱讀理解模擬題及參考答案(10)
At 18, Ashanthi DeSilva of suburban Cleveland is a living symbol of one of the great intellectual achievements of the 20th century. Born with an extremely rare and usually fatal disorder that left her without a functioning immune system (the “bubble-boy disease,” named after an earlier victim who was kept alive for years in a sterile plastic tent), she was treated beginning in 1990 with a revolutionary new therapy that sought to correct the defect at its very source, in the genes of her white blood cells. It worked. Although her last gene-therapy treatment was in 1992, she is completely healthy with normal immune function, according to one of the doctors who treated her, W. French Anderson of the University of Southern California. Researchers have long dreamed of treating diseases from hemophilia to cancer by replacing mutant genes with normal ones. And the dreaming may continue for decades more. “There will be a gene-based treatment for essentially every disease,” Anderson says, “within 50 years.”
It's not entirely clear why medicine has been so slow to build on Anderson's early success. The National Institutes of Health budget office estimates it will spend $432 million on gene-therapy research in 2005, and there is no shortage of promising leads. The therapeutic genes are usually delivered through viruses that don't cause human disease. “The virus is sort of like a Trojan horse,” says Ronald Crystal of New York Presbyterian/Weill Cornell Medical College. “The cargo is the gene.”
At the University of Pennsylvania's Abramson Cancer Center, immunologist Carl June recently treated HIV patients with a gene intended to help their cells resist the infection. At Cornell University, researchers are pursuing gene-based therapies for Parkinson's disease and a rare hereditary disorder that destroys children's brain cells. At Stanford University and the Children's Hospital of Philadelphia, researchers are trying to figure out how to help patients with hemophilia who today must inject themselves with expensive clotting drugs for life. Animal experiments have shown great promise.
But somehow, things get lost in the translation from laboratory to patient. In human trials of the hemophilia treatment, patients show a response at first, but it fades over time. And the field has still not recovered from the setback it suffered in 1999, when Jesse Gelsinger, an 18-year-old with a rare metabolic disorder, died after receiving an experimental gene therapy at the University of Pennsylvania. Some experts worry that the field will be tarnished further if the next people to benefit are not patients but athletes seeking an edge. This summer, researchers at the Salk Institute in San Diego said they had created a “marathon mouse” by implanting a gene that enhances running ability; already, officials at the World Anti-Doping Agency are preparing to test athletes for signs of “gene doping.” But the principle is the same, whether you're trying to help a healthy runner run faster or allow a muscular-dystrophy patient to walk. “Everybody recognizes that gene therapy is a very good idea,” says Crystal. “And eventually it's going to work.”
1. The case of Ashanthi Desilva is mentioned in the text to ____________.
[A] show the promise of gene-therapy
[B] give an example of modern treatment for fatal diseases
[C] introduce the achievement of Anderson and his team
[D] explain how gene-based treatment works
2. Anderson‘s early success has ________________.
[A] greatly speeded the development of medicine
[B] brought no immediate progress in the research of gene-therapy
[C] promised a cure to every disease
[D] made him a national hero
3. Which of the following is true according to the text?
[A] Ashanthi needs to receive gene-therapy treatment constantly.
[B] Despite the huge funding, gene researches have shown few promises.
[C] Therapeutic genes are carried by harmless viruses.
[D] Gene-doping is encouraged by world agencies to help athletes get better scores.
4. The word “tarnish” (line 5, paragraph 4) most probably means ____________.
[A] affect
[B] warn
[C] trouble
[D] stain
5. From the text we can see that the author seems ___________.
[A] optimistic
[B] pessimistic
[C] troubled
[D] uncertain
答案:A B C D A
2022考研初復試已經接近尾聲,考研學子全面進入2023屆備考,跨考為23考研的考生準備了10大課包全程準備、全年復習備考計劃、目標院校專業(yè)輔導、全真復試模擬練習和全程針對性指導;2023考研的小伙伴針也已經開始擇校和復習了,跨考考研暢學5.0版本全新升級,無論你在校在家都可以更自如的完成你的考研復習,暑假集訓營帶來了院校專業(yè)初步選擇,明確方向;考研備考全年規(guī)劃,核心知識點入門;個性化制定備考方案,助你贏在起跑線,早出發(fā)一點離成功就更近一點!
考研院校專業(yè)選擇和考研復習計劃 | |||
2023備考學習 | 2023線上線下隨時學習 | 34所自劃線院??佳袕驮嚪謹稻€匯總 | |
2022考研復試最全信息整理 | 全國各招生院校考研復試分數線匯總 | ||
2023全日制封閉訓練 | 全國各招生院??佳姓{劑信息匯總 | ||
2023考研先知 | 考研考試科目有哪些? | 如何正確看待考研分數線? | |
不同院校相同專業(yè)如何選擇更適合自己的 | 從就業(yè)說考研如何擇專業(yè)? | ||
手把手教你如何選專業(yè)? | 高校研究生教育各學科門類排行榜 |
相關推薦
跨考考研課程
班型 | 定向班型 | 開班時間 | 高定班 | 標準班 | 課程介紹 | 咨詢 |
秋季集訓 | 沖刺班 | 9.10-12.20 | 168000 | 24800起 | 小班面授+專業(yè)課1對1+專業(yè)課定向輔導+協(xié)議加強課程(高定班)+專屬規(guī)劃答疑(高定班)+精細化答疑+復試資源(高定班)+復試課包(高定班)+復試指導(高定班)+復試班主任1v1服務(高定班)+復試面授密訓(高定班)+復試1v1(高定班) | |
2023集訓暢學 | 非定向(政英班/數政英班) | 每月20日 | 22800起(協(xié)議班) | 13800起 | 先行階在線課程+基礎階在線課程+強化階在線課程+真題階在線課程+沖刺階在線課程+專業(yè)課針對性一對一課程+班主任全程督學服務+全程規(guī)劃體系+全程測試體系+全程精細化答疑+擇校擇專業(yè)能力定位體系+全年關鍵環(huán)節(jié)指導體系+初試加強課+初試專屬服務+復試全科標準班服務 |